What happened
Shares of biopharma Nektar Therapeutics (NKTR 4.41%) dropped over 11% today after the company released an abstract to be presented at the American Society of Clinical Oncology annual meeting next month that contained a disappointing update for an ongoing clinical trial.
The latest interim data analysis for a phase 1/2 trial evaluating a combination therapy of the company's drug candidate, NKTR-214, with Opdivo from Bristol-Myers Squibb showed significant drops in response rates compared to those released at the last interim data analysis in November 2017.
As of 12:41 p.m. EDT, the stock had settled to a 10.1% loss. But shares still boast year-to-date gains of 29% following a strong March.
Image source: Getty Images.
So what
The phase 1/2 trial is evaluating the drug candidate combo against a range of different cancers, including melanoma, kidney cancer, and non-small-cell lung cancer (NSCLC). As reported by FierceBiotech, the overall response rate (ORR) for the NKTR-214 and Opdivo combination has slipped as more patients have been evaluated.
|
Cancer Type |
Latest Data Readout, ORR / Patients |
November 2017 Data Readout, ORR / Patients |
|---|---|---|
|
Melanoma |
52% after 23 patients |
63% after 11 patients |
|
Kidney cancer |
54% with 24 patients |
71% with 13 patients |
|
NSCLC |
50% with 6 patients |
75% with 4 patients |
Source: FierceBiotech.
The combo also achieved an ORR of 75% and 33%, respectively, in three patients with triple-negative breast cancer and four with bladder cancer.
To be fair, response rates of 50% or greater are still pretty solid for a cancer drug combination. But analysts were obviously hoping that the even better response rates from November would hold as the patient population expanded.
Now what
The latest data readout from Nektar Therapeutics is just the most recent example of why size matters when it comes to clinical trials. While Wall Street can sometimes get carried away with what appear to be stellar results in small trials, it's best to wait for response rates to be confirmed in larger patient populations. That said, achieving an ORR of 50% or greater isn't bad, but now the question is: Will that continue to fall even further as the trial expands?
